SCHEMBL310648

SCHEMBL310648

CCOC(CF)=C(C#N)c1cccc(Cl)c1Cl

nearest known ligand 0.37

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TAS1R3 Q7RTX0 1/20 0.37
TAS1R1 Q7RTX1 1/20 0.37
TAS1R2 Q8TE23 1/20 0.37
TSHR P16473 4/20 0.36
ALDH1A1 P00352 4/20 0.35
LMNA P02545 3/20 0.35
SMN1; SMN2 Q16637 2/20 0.35
HTT P42858 1/20 0.34
MAPT P10636 3/20 0.34
ERCC5 P28715 1/20 0.33
FEN1 P39748 1/20 0.33
ALOX15 P16050 1/20 0.33
TDP1 Q9NUW8 1/20 0.33
CYP2C9 P11712 3/20 0.33
KDM4E B2RXH2 3/20 0.33
SLC6A3 Q01959 2/20 0.33
MEN1 O00255 2/20 0.33
CYP1A2 P05177 2/20 0.33
CYP3A4 P08684 2/20 0.33
CYP2C19 P33261 2/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL310647 1.00 TAS1R3 (0.37) TAS1R3TAS1R1TAS1R2TSHRALDH1A1
SCHEMBL7767206 0.78 TAS1R3 (0.38) TAS1R3TAS1R1TAS1R2TSHRALDH1A1
SCHEMBL7767210 0.78 TAS1R3 (0.38) TAS1R3TAS1R1TAS1R2TSHRALDH1A1
SCHEMBL7772728 0.78 TSHR (0.44) TAS1R3TAS1R1TAS1R2TSHRALDH1A1
SCHEMBL7772729 0.78 TSHR (0.44) TAS1R3TAS1R1TAS1R2TSHRALDH1A1
SCHEMBL5070752 0.76 TAS1R3 (0.38) TAS1R3TAS1R1TAS1R2TSHRALDH1A1
SCHEMBL5070753 0.76 TAS1R3 (0.38) TAS1R3TAS1R1TAS1R2TSHRALDH1A1
Nitrous Acid SCHEMBL7767260 0.74 ALDH1A1 (0.40) TAS1R3TAS1R1TAS1R2TSHRALDH1A1
SCHEMBL5069210 0.70 TSHR (0.37) TAS1R3TAS1R1TAS1R2TSHRALDH1A1
SCHEMBL5069211 0.70 TSHR (0.37) TAS1R3TAS1R1TAS1R2TSHRALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8093268-B2 Pharmaceutical compositions comprising 2-methoxy-5-(5-trifluoromethyl-tetrazol-1-yl-benzyl)-(2S-phenylpiperidin-3S-yl-) GLAXO GROUP LIMITED (GB) 2012-01-10 US disclosed
US-20100113521-A1 PHARMACEUTICAL COMPOSITIONS COMPRISING 2-METHOXY-5-(5-TRIFLUOROMETHYL-TETRAZOL-1-YL-BENZYL)-(2S-PHENYLPIPERIDIN-3S-YL-) GLAXO GROUP LIMITED (GB) 2010-05-06 US disclosed
US-20100105688-A1 PHARMACEUTICAL COMPOSITIONS COMPRISING 3,5-DIAMINO-6-(2,3-DICHLOPHENYL)-1,2,4-TRIAZINE OR R(-)-2,4-DIAMINO-5-(2,3-DICHLOROPHENYL)-6-FLUOROMETHYL PYRIMIDINE AND AN NK1 GLAXO GROUP LIMITED (GB) 2010-04-29 US disclosed
EP-2129381-A1 PHARMACEUTICAL COMPOSITIONS COMPRISING 3, 5-DIAMIN0-6- (2, 3-DICHL0PHENYL) -L, 2, 4-TRIAZINE OR R (-) -2, 4-DIAMINO-5- (2, 3-DICHLOROPHENYL) -6-FLUOROMETHYL PYRIMIDINE AND AN NK1 Glaxo Group Limited (GB) 2009-12-09 EP disclosed
EP-2117538-A1 PHARMACEUTICAL COMPOSITIONS COMPRISING 2-METHOXY-5- (5-TRIFLUOROMETHYL-TETRAZOL-I-YL-BENZYL) - (2S-PHENYL-PIPERIDIN-3S-YL-) Glaxo Group Limited (GB) 2009-11-18 EP disclosed
WO-2008090114-A1 PHARMACEUTICAL COMPOSITIONS COMPRISING 2-METHOXY-5- (5-TRIFLUOROMETHYL-TETRAZOL-I-YL-BENZYL) - (2S-PHENYL-PIPERIDIN-3S-YL-) GLAXO GROUP LIMITED (GB) 2008-07-31 WO disclosed
WO-2008090117-A1 PHARMACEUTICAL COMPOSITIONS COMPRISING 3, 5-DIAMIN0-6- (2, 3-DICHL0PHENYL) -L, 2, 4-TRIAZINE OR R (-) -2, 4-DIAMINO-5- (2, 3-DICHLOROPHENYL) -6-FLUOROMETHYL PYRIMIDINE AND AN NK1 GLAXO GROUP LIMITED (GB) 2008-07-31 WO disclosed
EP-0879230-B1 OPTICALLY ACTIVE PHENYL PYRIMIDINE DERIVATIVE AS ANALGESIC AGENT GLAXO GROUP LTD (GB) 2001-07-25 EP disclosed
US-6124308-A ANALGESICS, ANTICONVULSANTS, TREATING IRRITABLE BOWEL SYNDROME OR BIPOLAR DISORDER GLAXO WELLCOME INC. (US) 2000-09-26 US disclosed
EP-0879230-A2 OPTICALLY ACTIVE PHENYL PYRIMIDINE DERIVATIVE AS ANALGESIC AGENT GLAXO GROUP LIMITED (GB) 1998-11-25 EP disclosed
WO-1997009317-A2 OPTICALLY ACTIVE PHENYL PYRIMIDINE DERIVATIVE AS ANALGESIC AGENT GLAXO GROUP LIMITED (GB) 1997-03-13 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100105688-A1 PHARMACEUTICAL COMPOSITIONS COMPRISING 3,5-DIAMINO-6-(2,3-DICHLOPHENYL)-1,2,4-TRIAZINE OR R(-)-2,4-DIAMINO-5-(2,3-DICHLOROPHENYL)-6-FLUOROMETHYL PYRIMIDINE AND AN NK1 KCNJ2, SCN5A, GRIK5 TAS1R3 1551/4885TAS1R1 1632/4885TAS1R2 1007/4885
US-20100113521-A1 PHARMACEUTICAL COMPOSITIONS COMPRISING 2-METHOXY-5-(5-TRIFLUOROMETHYL-TETRAZOL-1-YL-BENZYL)-(2S-PHENYLPIPERIDIN-3S-YL-) KCNJ2, TRPV1, SCN5A TAS1R3 1163/4885TAS1R1 1398/4885TAS1R2 1026/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.